Clinical Report: Reevaluating the Role of Low-Dose Aspirin in GCA
Overview
This study evaluates the association of low-dose aspirin with the prevention of major adverse cardiovascular events (MACE) in patients with giant cell arteritis (GCA). Findings suggest a significant reduction in MACE and all-cause mortality at one year, but an increased risk of major hemorrhage, leading to neutral net clinical benefits over time.
Background
Giant cell arteritis (GCA) is a critical condition that can lead to severe ischemic complications, including vision loss and cerebrovascular events. Cardiovascular outcomes are also significant contributors to morbidity and mortality in GCA patients, especially older individuals with comorbidities. The role of low-dose aspirin in this context remains unclear, as current guidelines do not support its routine use for primary cardiovascular prevention in GCA.
Data Highlights
Outcome
Relative Risk (RR)
95% Confidence Interval (CI)
MACE
0.86
0.75 to 0.96
All-cause mortality
0.82
0.68 to 0.95
Major hemorrhage
1.29
1.05 to 1.53
Net clinical benefits at 1 year
1.02
0.90 to 1.13
Net clinical benefits at 3 years
0.93
0.86 to 1.00
Key Findings
Low-dose aspirin was associated with a significant reduction in MACE at 1 year (RR, 0.86).
All-cause mortality also decreased significantly with low-dose aspirin (RR, 0.82).
An increased risk of major hemorrhage was observed (RR, 1.29).
Net clinical benefits were neutral at 1 year (RR, 1.02) and at 3 years (RR, 0.93).
The risk of bleeding with low-dose aspirin attenuated over time, becoming non-significant at 3 years.
Clinical Implications
Clinicians should weigh the potential ischemic benefits of low-dose aspirin against the risk of major hemorrhage in patients with GCA. Given the neutral net clinical benefits observed, routine use of low-dose aspirin for primary cardiovascular prevention in GCA may not be warranted.
Conclusion
The findings from this study highlight the complexity of managing cardiovascular risk in GCA patients and suggest that further research is needed to clarify the role of low-dose aspirin in this population.
